Friends Research Institute
Los Angeles, California, 90025, United States
NCT Number: NCT00000344
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment.
Looking for future studies?
Notify Me21 year–50 year
All sexes
Interventional
Phase 2
Los Angeles, California, 90025, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
M/F ages 21-50. Meet DSM-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent.
Exclusion criteria
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
National Institute on Drug Abuse (NIDA)
Nih
Trial of Buprenorphine/Naloxone for Treatment of Opiate Dependence
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06134882
Chemically-Induced Disorders, Drug Abuse
Kalamazoo, Michigan, United States
View Trial DetailsNCT06862752
Chemically-Induced Disorders, Mental Disorders
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05480956
Blood-Borne Infections, Chemically-Induced Disorders
Birmingham, Alabama, United States
View Trial DetailsNCT04499079
Behavior, Chemically-Induced Disorders
Indianapolis, Indiana, United States
View Trial Details